Marker Therapeutics, Inc.
MRKR
$0.88
-$0.04-3.95%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.39M | 5.70M | 6.59M | 5.40M | 3.73M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.39M | 5.70M | 6.59M | 5.40M | 3.73M |
| Cost of Revenue | 15.87M | 14.03M | 13.47M | 11.00M | 9.57M |
| Gross Profit | -10.48M | -8.33M | -6.88M | -5.60M | -5.85M |
| SG&A Expenses | 4.20M | 4.39M | 4.24M | 4.59M | 5.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.07M | 18.42M | 17.71M | 15.59M | 14.72M |
| Operating Income | -14.68M | -12.72M | -11.12M | -10.19M | -10.99M |
| Income Before Tax | -14.56M | -12.73M | -10.68M | -9.63M | -10.30M |
| Income Tax Expenses | 50.00K | 50.00K | 50.00K | 3.70K | 3.70K |
| Earnings from Continuing Operations | -14.61 | -12.78 | -10.73 | -9.63 | -10.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -62.90K | -62.90K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.61M | -12.78M | -10.73M | -9.70M | -10.37M |
| EBIT | -14.68M | -12.72M | -11.12M | -10.19M | -10.99M |
| EBITDA | -- | -- | -- | -2.24M | -4.74M |
| EPS Basic | -1.36 | -1.32 | -1.19 | -1.09 | -1.17 |
| Normalized Basic EPS | -0.82 | -0.80 | -0.74 | -0.68 | -0.73 |
| EPS Diluted | -1.37 | -1.33 | -1.20 | -1.09 | -1.17 |
| Normalized Diluted EPS | -0.82 | -0.80 | -0.74 | -0.68 | -0.73 |
| Average Basic Shares Outstanding | 43.16M | 38.12M | 35.92M | 35.63M | 35.54M |
| Average Diluted Shares Outstanding | 43.16M | 38.12M | 35.92M | 35.63M | 35.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |